
PASSAGE BIO (PASG) Stock Forecast & Price Target
PASSAGE BIO (PASG) Analyst Ratings
Bulls say
Passage Bio Inc's focus on developing transformative therapies for rare, monogenic central nervous system disorders has positioned the company favorably within the genetic medicines sector. Recent interim data has demonstrated sustained mean cerebrospinal fluid PGRN increases, indicating the potential for enhanced efficacy of their lead product, PBFT02, and suggesting a probable advantage over competing treatments due to a streamlined dosing procedure. Moreover, the possibility of securing regulatory alignment for accelerated approval based on biomarker endpoints could significantly reduce trial timelines, potentially enhancing future revenue prospects and overall company valuation.
Bears say
Passage Bio Inc faces significant challenges that contribute to a negative outlook on its stock, primarily associated with the inherent risks in clinical developments and potential safety issues with its gene therapy programs, namely PBGM01 and PBFT02. There are concerns regarding possible delays in clinical timelines and emerging safety signals that could adversely affect market sentiment and result in downward revisions to the company's financial forecasts. Additionally, uncertainties surrounding manufacturing capacity could further constrain the company's expected growth and operational capabilities, highlighting a precarious financial position amid the competitive landscape of genetic medicines.
This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.
PASSAGE BIO (PASG) Analyst Forecast & Price Prediction
Start investing in PASSAGE BIO (PASG)
Order type
Buy in
Order amount
Est. shares
0 shares